https://66615inhibitor.com/usp....13-mediates-pten-to-
Notably, sST2 is a soluble form of ST2 that lacks a transmembrane domain but preserves an extracellular domain comparable to ST2L, which will act as a "decoy" receptor for IL-33. sST2 has been shown to involve into the inflammatory tumefaction microenvironment additionally the progression of colorectal cancer, non-small cell lung cancer, and gastric cancer tumors. Consequently, concentrating on the IL-33/ST2 axis becomes a promising new immunotherapy for therapy of several typ
Like
Comment
Share
